Vericel Corporation earnings per share and revenue
On Nov 06, 2025, VCEL reported earnings of 0.10 USD per share (EPS) for Q3 25, beating the estimate of 0.00 USD, resulting in a 1662.50% surprise. Revenue reached 67.50 million, compared to an expected 65.85 million, with a 2.50% difference. The market reacted with a +4.17% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of 0.40 USD, with revenue projected to reach 92.62 million USD, implying an increase of 300.00% EPS, and increase of 37.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were Vericel Corporation's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Vericel Corporation reported EPS of $0.10, beating estimates by 1662.5%, and revenue of $67.50M, 2.5% above expectations.
How did the market react to Vericel Corporation's Q3 2025 earnings?
The stock price moved up 4.17%, changed from $37.20 before the earnings release to $38.75 the day after.
When is Vericel Corporation expected to report next?
The next earning report is scheduled for Feb 26, 2026.
What are the forecasts for Vericel Corporation's next earnings report?
Based on 10
analysts, Vericel Corporation is expected to report EPS of $0.40 and revenue of $92.62M for Q4 2025.